2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

628. Aggressive Lymphomas: Cellular Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Clinical Procedures, Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult
PAPER

1925 Anti-CD19 CAR T-cells therapy is an effective and safe treatment option for patients with relapsed or refractory mediastinal gray zone lymphoma

Aliénor Gilardoni, Jean Galtier2, Loïc Renaud, MD3, Marie Donzel4, Vincent Camus, MD, PhD5, Gaspar Aspas Requena, MD6, Laure Lebras, MD7, Roberta Di Blasi, MD, PhD8, Thomas Gastinne, MD9, Amandine Fayard10, Guillaume Manson, MD11, Magalie Joris, MD12, Lucile Bussot13, Elise Toussaint14, Jerome Paillassa, PhD15, Gabriel Brisou, MD PhD16, Luc Matthieu Fornecker17, Peggy Dartigues18, Camille Bigenwald, MD19, David Beauvais, MD20, Catherine Chassagne-Clément Sr, PhD21, Romain Dubois22, Marie-Christine Copin Sr, PhD23, Steven Le Gouill, MD PhD24, Roch Houot, MD, PhD25, Alexandra Traverse Glehen, MD PhD26, Pierre Sesques, PhD27, Clémentine Sarkozy, MD,PhD28
1 Sorbonne Université, Paris, France
2 Hôpital Haut-Lévêque, Bordeaux, France
3 Hôpital Cochin, Paris, France
4 Hôpital Lyon-Sud, Lyon, France, Hospices Civils de Lyon, Lyon, France
5 Centre Henri Bécquerel, Rouen, France
6 CHU Nîmes, Nîmes, France
7 Centre Léon Bérard, Lyon, France
8 Hôpital Saint-Louis, Paris, France
9 CHU Nantes, Nantes, France
10 CHU Clermont-Ferrand, Clermont-Ferrand, France
11 CHU Rennes, Rennes, France
12 CHU Amiens, Amiens, France
13 CHU Grenoble, Grenoble, France
14 Hôpital de Hautepierre, Strasbourg, France
15 CHU Angers, Angers, France
16 Institut Paoli-Calmettes, Marseilles, France
17 Hôpital de Hautepierre, Strasbourg, France
18 Institut Gustave Roussy, Villejuif, France
19 Institut Gustave Roussy, Villejuif, France
20 CHU Lille, Lille, France
21 Centre Léon Bérard, Lyon, France
22 CHU Lille, Lille, France
23 CHU Angers, Angers, France
24 Institut Curie, Saint-Cloud, France
25 CHU Rennes, Rennes, France
26 CHU Lyon Sud, Lyon, France
27 CHU Lyon Sud, Lyon, France
28 Institut Curie, Saint-Cloud, France

Introduction: Mediastinal Gray Zone lymphoma (MGZL) is a rare B-cell lymphoma with overlapping features between primary mediastinal B-cell (PMBCL) and classic Hodgkin lymphoma (CHL). Over 30-40% of cases are refractory to standard immuno-chemotherapy (ICT). Given the rarity of the disease, MGZL are usually not included in clinical trials and data on the safety and efficacy of anti-CD19 CAR T-cell therapy have not been reported so far.

Methods: We conducted a retrospective, multicenter, observational study within the DESCAR-T registry that prospectively collects all outcome and toxicity data for patients treated with CAR T-cell in France. 

Patients with diagnosis of relapsed or refractory (R/R) MGZL treated with a commercial CAR T-cell product were included. All the MGZL diagnoses were initially reviewed in the context of the LYMPHOPATH registry in France, and pathological reports were subsequently reviewed by 2 experts in hematopathology (ATG, MD) in line with the 2022-WHO criteria. Cases were classified as PMBCL-like or CHL-like, based on morphology and immunohistochemical features. The primary endpoint was overall response rate (ORR), secondary endpoints were progression-free survival (PFS) and overall survival (OS). 

A cohort of PMBCL cases was used as a comparator (N=80). We performed an exploratory multivariate analysis including disease type (MGZL vs. PMBCL), number of prior treatment lines (≥2 vs. 1), Ann Arbor stage (III-IV vs. I-II), lactate dehydrogenase (LDH) level at infusion (above upper limit of normal [ULN] vs. normal) and type of CAR T-cell infused (Tisagenlecleucel [Tisa-cel] or Lisocabtagene-maraleuce [Liso-cel] vs. Axicabtagene-ciloleucel [Axi-cel]).

Results: From May 2019 to May 2026, 30 patients were recorded in the DESCAR-T registry as GZL or mediastinal GZL. After scrutiny of clinical and pathological reports, 15 fulfilling the strict 2022 WHO classification definition criteria of MGZL were included in this study. Of these, 7 (46.7%) were classified as CHL-like and 8 (53.3%) as PMBCL-like, while 2 patients had a R/R MGZL with an initial diagnosis of CHL. Median age was 41 years (range 19-74, IQR 21). The median number of prior lines was 2 (range 1-4). Eight patients (53.3%) received Axi-cel, 5 (33.3%) Tisa-cel and 2 (13.3%) Liso-cel. At time of infusion, 40% had a stage III-IV, 93.4% a low (0-1) aaIPI, 33.3% a bulky disease and 13.3% LDH>ULN. The median time from apheresis to infusion was 43 days (range 29-109). Bridging therapy was administered in 86.7% of cases, including immune check-point inhibitors in 30.8%, ICT in 53.8%. ORR to bridging therapy was 38.4%. 

Median follow-up post infusion was 31,7 months. ORR were 53% (8/15) at M1 and M3 and complete response rate (CRR) 33.3% (5/15) at M1 and 40% (6/15) at M3. No relapse occurred among patients in CR, while one patient in PR at M1 relapsed at M3. Median PFS was 19.5m [range 1-not reached (NR)] and median OS was NR, while estimated 1y PFS and OS were 53.3% and 86.7%, 2y PFS and OS were 42.7% and 77% respectively. CD19 expression was not related to treatment response. 

Among the 4 deaths (27%), 3 were related to lymphoma and one to secondary AML (in CR). Cytokine-releasing syndrome (CRS) occurred in 73.3% (11) of patients and 26.7% (4) had an immune effector cell-associated syndrome (ICANS) (all grade 1-2). Grade 3-4 neutropenia occurred in 40% and grade 3-4 infections in 33.3% of patients. 

Within the PMBCL cohort, ORR at M1 was 78% and M3 80%, M1 CRR was 41% and M3 CRR 61%. After a median follow-up of 35.5m, median PFS was 49.8m (range 12.7-NR), median OS was NR, 2-year PFS and OS were 59.6% and 75.6% respectively, without significant distinction compared to MGZL in an unadjusted analysis (log-rank p value for PFS = 0.4 and 0.9 for OS). In a multivariate analysis including 15 MGZL and 73 PMBCL with available clinical data, advanced stage disease (Ann Arbor stage III-IV) and CAR-T type (Tisa-cel vs. other) were associated with a shorter PFS (HR for Ann Arbor stage = 2.2 [1.02; 4.74], p = 0.045; HR for Tisa-cel = 4.65 [1.98; 10.92], p < 0.001) while the diagnosis (MGZL vs. PMBCL), LDH level and number of prior lines were not.

Conclusion: We report for the first time that CAR T-cells therapy is an effective and safe option for R/R MGZL. Using a companion cohort of PMBCL cases, we further showed that MGZL patients seem to have a comparable outcome post CAR T-cells compared to PMBCL. Additional studies are needed to confirm our data in larger cohorts.

Aliénor Gilardoni: No relevant conflicts of interest to declare.